666721-06-8

Basic information

• Product Name: 2-Thiophenecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-
• CAS NO: 666721-06-8
• Molecular Formula: C12H7F3O3S
• Molecular Weight: 288.247
• Mol File: 666721-06-8.mol

Chemical Properties

• CAS DataBase Reference: 2-Thiophenecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiophenecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-(666721-06-8)
• EPA Substance Registry System: 2-Thiophenecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-(666721-06-8)

Safety Data

• Hazardous Substances Data: 666721-06-8(Hazardous Substances Data)

Upstream product

• 666721-05-7 4-[4-(trifluoromethoxy)phenyl]thiophene-2-carbaldehyde 
• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 16694-18-1 4-bromo-thiophene-2-carboxylic acid 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 

Downstream Products

• 666721-60-4 trans-4-({[4-(4-trifluoromethoxyphenyl)thien-2-yl]-carboxamido}methyl)cyclohexanecarboxylic acid 
• 820223-49-2 (R)-{[4-(4-trifluoromthoxyphenyl)thien-2-yl]carboxamido}(phenyl)propanoic acid 
• 666721-04-6 4-[4-(trifluoromnethoxy)phenyl]thiophene-2-carbonyl chloride 

Relevant articles and documents

Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors

A new class of MMP-12 inhibitors was discovered and optimized using structure-based drug design methods. Modeling studies using a known MMP-12 crystal structure identified a new interaction mode for these new MMP-12 inhibitors. Further optimization resulted in the discovery of a compound displaying nanomolar activity against MMP-12 and which was co-crystallized with MMP-12.

THIOPHENE AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I), in which: R1 and R2, which may be identical or different, independently of each other, each represent a group selected from: hydrogen, halogen, cyano, nitro, halo(C1-C6)alkyl, halo(Csu

5-FLUORO-THIOPEN-COMPOUNDS,THE PROCESS FOR THEIR PREPARATION,THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS METALLOPOTENASES INHIBITORS

Compounds of formula (I) in which R1 represent a group selected from halo(C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, phenyl, cyclohexyl an

Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them

A compound of formula (I) selected from: wherein: X represents oxygen or sulphur, Y represents oxygen, —NH— or —N(C1-C6)alkyl-, Ra represents hydrogen, halogen, (C1-C3)alkyl, hydroxyl or (C1-C3)alkoxy, Rb represents hydrogen, halogen or (C1-C3)alkyl, A represents phenyl, pyridyl, (C5-C6)cycloalkyl or (C5-C6)cycloalkenyl, R1 and R2 each represent a group selected from hydrogen, halogen, cyano, nitro, haloalkyl, haloalkoxy, alkyl, alkenyl, alkynyl, —OR4, —NR4R5, —S(O)nR4, —C(O)R4, —CO2R4, —O—C(O)R4, —C(O)NR4R5, —NR5—C(O)R4, —NR5—SO2R4, -T-CN, -T-OR4, -T-OCF3, -T- NR4R5, -T-S(O)nR4, -T-C(O)R4, -T-CO2R4, -T-O—C(O)R4, -T-C(O)NR4R5, -T-NR4—C(O)R5, -T-NR4—SO2R5, —R6 and -T-R6 in which n, T, R4, R5 and R6 are as defined in the description, R3 represents an —R7 or —U—R11 group in which R7 represents hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U represents a linear or branched alkylene chain and R11 is defined in the description, their optical isomers or their addition salts with a pharmaceutically acceptable acid or base, and their use as inhibitor of metalloproteinase and more specifically of metalloproteinase-12.